Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone510-550-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.82 million
Profitability
Miscellaneous
Employees68
OptionableOptionable
Zogenix (NASDAQ:ZGNX) Frequently Asked Questions
What is Zogenix's stock symbol?
Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."
How were Zogenix's earnings last quarter?
Zogenix, Inc. (NASDAQ:ZGNX) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($1.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.88) by $0.20. During the same quarter in the prior year, the firm posted ($1.68) earnings per share. View Zogenix's Earnings History.
When is Zogenix's next earnings date?
What price target have analysts set for ZGNX?
9 brokerages have issued 1 year target prices for Zogenix's shares. Their predictions range from $60.00 to $116.00. On average, they anticipate Zogenix's stock price to reach $73.00 in the next year. This suggests a possible upside of 69.2% from the stock's current price. View Analyst Price Targets for Zogenix.
What is the consensus analysts' recommendation for Zogenix?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.
What are Wall Street analysts saying about Zogenix stock?
Here are some recent quotes from research analysts about Zogenix stock:
- 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel DosePro is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (1/19/2019)
- 2. Mizuho analysts commented, "We continue to see Fintepla as highly differentiated from competitor products with the potential for higher pricing and market share. The most important catalyst is a potential FDA approval in DS in 2019. Beyond DS, we see potential for for which data is anticipated in 1Q20." (12/6/2018)
Has Zogenix been receiving favorable news coverage?
Media coverage about ZGNX stock has been trending very positive on Tuesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zogenix earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are some of Zogenix's key competitors?
Some companies that are related to Zogenix include Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX) and Taro Pharmaceutical Industries (TARO).
Who are Zogenix's key executives?
Zogenix's management team includes the folowing people:
- Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
- Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 66)
- Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
- Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
- Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
Who are Zogenix's major shareholders?
Zogenix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (0.06%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Institutional Ownership Trends for Zogenix.
Which major investors are selling Zogenix stock?
ZGNX stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Erle T Mast, Gail M Farfel, Roger Hawley and Stephen J Farr. View Insider Buying and Selling for Zogenix.
How do I buy shares of Zogenix?
Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zogenix's stock price today?
One share of ZGNX stock can currently be purchased for approximately $43.15.
How big of a company is Zogenix?
Zogenix has a market capitalization of $1.81 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.
What is Zogenix's official website?
How can I contact Zogenix?
Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]
MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
